House of Commons photoWon his last election, in 2015, with 43% of the vote.
Health June 19th, 2006
Mr. Speaker, nothing could be further from the truth. As with all other members of this House, I hire people I have confidence in. I certainly was pleased with the work of the individual involved. Much as this was not the case when the hon. member and her colleagues were in power, I followed all the rules.
Starred Questions June 16th, 2006
Mr. Speaker, the answer is as follows: a) The Government of Canada intends to compensate those infected with hepatitis C through the Canadian blood system before 1986 and after 1990 as quickly as possible. Much work is underway on the steps needed to reach an agreement with the class. Given that this is a negotiation, no firm date can be provided as to when an agreement will be reached, but the Government of Canada is ensuring that all necessary steps in this process, that are within its control, are completed as quickly as possible.
b) Upon taking office, the Government of Canada immediately proceeded with its campaign commitment--work is ongoing. The most recent negotiating session was held on May 24-26, 2006. This is a complex issue with many stakeholders, and the Government of Canada is working diligently to provide compensation to the class as quickly as possible.
c) For the issues that it is able to influence, the Government of Canada is taking all possible steps to quickly reach an agreement with the class and provide compensation. The Government of Canada will proceed as quickly as possible but some factors are outside of the government’s control, for example, the process of obtaining court approvals of any proposed settlement agreement. After court approval, an administrative process to evaluate and pay compensation must be established.
d) As per the memorandum of understanding signed by both sides in November 2005, determining the eligibility criteria for compensation is part of the process of settling with the class. Compensation programs established to date, the 1986-1990 agreement, the Red Cross settlement, and provincial compensation programs, have used an application and evaluation process to determine eligibility. Eligibility criteria, and a process to evaluate eligibility and compensate class members will be established in a final settlement.
Questions on the Order Paper June 15th, 2006
Mr. Speaker, the answer is as follows:
a) Compensation to those infected by hepatitis C through the Canadian blood system has been provided by numerous sources. Approximately 6000 individuals were compensated through the federal/provincial/territorial agreement reached in 1999 to compensate those infected from January 1, 1986 to July 1, 1990. Individuals infected outside this window have received compensation through the insolvency of the Red Cross and depending on the province, from their provincial governments.
b) There is no definition of “full compensation”. One way to interpret full compensation is when the Courts have approved compensation packages as being in the best interests of the class and fair. The 1986-1990 class has received a generous compensation package and approximately 6000 individuals have received it.
c) If this is intended to mean those who are waiting for compensation from the federal government, the exact class size would be determined through the eligibility criteria of a final settlement agreement.
d) The Government of Canada fully intends to proceed with its commitment to provide compensation to those infected with hepatitis C through the blood system. Discussions are taking place with counsel representing those infected before January 1, 1986 and after July 1, 1990. Much work is taking place at the present time to make progress on a settlement and a compensation arrangement. Given that this is a negotiation, no firm date can be given as to when a final agreement will be reached, but the government is committed to compensating the class as quickly as possible.
e) Both parties in the negotiation have agreed that the substance of the discussions would remain between them, and stay at the negotiating table. I must respect this agreement but I can assure you that significant work is underway at the present time to make progress on a final settlement agreement. Discussions are taking place and we will compensate the class as quickly as possible. The most recent negotiating session was held May 24-26, 2006.
Health June 14th, 2006
Mr. Speaker, I thank the hon. member for her advice. It is important to us but we also require the advice of scientists. We are also reviewing best practices in other jurisdictions. When we have a strategy that we think will protect the health and safety of Canadians we will table it in the House.
Health June 14th, 2006
Mr. Speaker, I want to acknowledge what happened a couple of years ago in this place. I understand at the time the member for Winnipeg Centre forged a coalition in the House to put a resolution forward. Since that time there has been a multi-stakeholder task force that has been reviewing the issue and reviewing the science. When the review is complete and the science is before us, then we can make a decision.
Health June 14th, 2006
Mr. Speaker, it is clear, on reading section 90, that the minister does not have the power to demand an answer to a regulatory question or to demand an opinion regarding drug prices.
It is a quasi-judicial agency. It is an independent body. From this side of the House, it is impossible for me to raise this question with the board.
Health June 14th, 2006
Mr. Speaker, I will give the same answer as yesterday. I would like to tell this House that the board is an independent body with quasi-judicial powers. In this House, I cannot get involved.
Health June 13th, 2006
Mr. Speaker, the Patented Medicine Prices Review Board can determine if the price is excessive. In such case, it is possible that it has the requisite authority to have the price lowered. It is a quasi-judicial board, independent from the government. I support this system.
Health June 13th, 2006
Mr. Speaker, I would like to say to this House that the Patented Medicine Prices Review Board is an independent agency with quasi-judicial authority. It is impossible to intervene in this situation because it is up to the Patented Medicine Prices Review Board to make that decision.
Health June 9th, 2006
Mr. Speaker, I do not agree with the hon. member.
It is important to protect women and there is a process for accessing these implants. It is important to protect patients, and there is another process for access to drugs. Nonetheless, if there is a need, I will support it.